List of Excipients in Branded Drug E-Z-PAQUE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
E-Z-EM Canada Inc	E-Z-PAQUE	barium sulfate	32909-186	ANHYDROUS CITRIC ACID
E-Z-EM Canada Inc	E-Z-PAQUE	barium sulfate	32909-186	CARBOXYMETHYLCELLULOSE SODIUM
E-Z-EM Canada Inc	E-Z-PAQUE	barium sulfate	32909-186	DIMETHICONE 1000
E-Z-EM Canada Inc	E-Z-PAQUE	barium sulfate	32909-186	DIMETHICONE 350
E-Z-EM Canada Inc	E-Z-PAQUE	barium sulfate	32909-186	POLYSORBATE 80
E-Z-EM Canada Inc	E-Z-PAQUE	barium sulfate	32909-186	POTASSIUM SORBATE
E-Z-EM Canada Inc	E-Z-PAQUE	barium sulfate	32909-186	SACCHARIN SODIUM

E-Z-PAQUE Excipient Strategy and Commercial Opportunities: Formulation, Regulatory, Patent and Generic-Entry Analysis

Last updated: August 9, 2026

E-Z-PAQUE is a barium sulfate oral contrast product used for radiographic examination of the esophagus and upper gastrointestinal tract. Its commercial value is driven by radiopacity, rapid and uniform dispersion, swallowability, flavor, dose convenience, and hospital workflow rather than by molecular exclusivity. The strongest opportunities are excipient optimization, ready-to-use packaging, differentiated viscosity and flavor profiles, and regulatory pathways for competing barium sulfate products. Barium sulfate is an old diagnostic active ingredient, so durable protection is more likely to arise from formulation, device, packaging, process, or use claims than from composition-of-matter patents.

What is E-Z-PAQUE and how does its formulation create commercial value?

E-Z-PAQUE is a high-concentration oral barium sulfate suspension marketed by Bracco Diagnostics. Barium sulfate is the radiopaque active ingredient. It is not systemically absorbed in meaningful amounts and passes through the gastrointestinal tract after administration.[1]

The product’s value proposition depends on five formulation attributes:

Attribute	Commercial function	Excipient implication
High barium concentration	Produces adequate radiographic contrast	Requires suspension stability and controlled viscosity
Uniform dose delivery	Supports consistent imaging	Requires wetting, suspending and anti-settling systems
Oral acceptability	Improves patient compliance	Requires flavor, sweetness and mouthfeel optimization
Rapid preparation	Reduces radiology-room labor	Favors ready-to-use presentations
Gastrointestinal transit	Supports imaging without excessive retention	Requires control of viscosity, osmolality and bulk properties

The principal formulation challenge is maintaining a dense suspension of insoluble barium sulfate. High solids loading increases sedimentation risk, viscosity, particle-particle interaction and difficulty in redispersion. The excipient system must prevent hard caking while preserving flow through the container and swallowability by the patient.

What excipients are used in E-Z-PAQUE?

The FDA-approved labeling identifies barium sulfate as the active ingredient and lists formulation components that support suspension stability, palatability, preservation and pH control.[1] Public product information identifies excipient functions including suspending agents, buffering or acidifying agents, sweeteners, flavoring components and preservatives.

Exact excipient levels are not generally disclosed in the public label. Commercial development should therefore distinguish between:

1. Publicly disclosed qualitative composition, which supports regulatory and competitive analysis.
2. Confidential quantitative composition, which may be protected as manufacturing know-how.
3. Performance specifications, such as viscosity, particle-size distribution, sedimentation rate, redispersibility and radiographic attenuation.

The most commercially relevant excipient classes are:

Suspending and rheology-modifying agents

Cellulose derivatives, xanthan gum and related hydrocolloids can increase low-shear viscosity, reduce sedimentation and improve dose uniformity. Their concentration must remain low enough to preserve pourability and swallowing.

The key development target is often shear-thinning behavior. A product should be sufficiently viscous at rest to limit settling but become easier to pour and swallow under applied force. Excessive polymer loading can produce a thick mouthfeel, slow gastrointestinal transit or create inconsistent dosing from partially settled containers.

Wetting and dispersion aids

Barium sulfate particles require efficient wetting and dispersion. Poor wetting causes agglomeration, air entrapment and nonuniform radiopacity. Wetting strategies may include controlled surfactant use, particle-size engineering, pre-wetting during manufacture and optimized mixing order.

Surfactants must be assessed for taste, foaming, gastrointestinal tolerance and compatibility with the container closure system. A low-foam process can have greater operational value than a nominal reduction in raw-material cost.

Buffering and pH-control agents

Citrate systems and related pH modifiers can support chemical and physical stability. pH affects polymer hydration, preservative performance, flavor perception and the interaction of formulation components.

A successful pH system must also avoid excessive acidity or salt loading. High ionic strength can alter hydrocolloid viscosity and suspension behavior.

Sweeteners and flavors

Taste is a meaningful commercial differentiator because barium sulfate preparations are administered in relatively large volumes. Sweeteners, flavors and cooling or masking agents can improve patient acceptance, particularly in pediatric, geriatric and dysphagia populations.

Flavor selection should be segmented by use case:

• Vanilla or cream profiles for general adult use.
• Fruit profiles for pediatric applications.
• Low-sugar or sugar-free systems for metabolic-risk populations.
• Low-intensity profiles for patients with nausea or altered taste perception.

Flavor systems create formulation and regulatory complexity. They can affect viscosity, preservative performance, container sorption and stability. Flavor changes may also require comparative human acceptability data even when radiographic performance is unchanged.

Preservatives

Preservatives can support multidose presentation, but many radiology products use single-dose packaging to reduce microbial and dosing risks. A move from multidose to unit-dose packaging can eliminate or reduce preservative requirements, simplify excipient qualification and improve hospital handling.

The tradeoff is higher packaging and logistics cost. Unit-dose packaging is most attractive where infection-control procedures, rapid patient turnover or protocol standardization justify the premium.

What formulation patents could protect an E-Z-PAQUE competitor?

The underlying barium sulfate active ingredient is unlikely to provide meaningful composition-of-matter exclusivity. A competing product would need to examine several narrower protection categories.

Protection category	Potential claim subject	Relative opportunity
Suspension composition	Barium sulfate concentration plus polymer, buffer, sweetener and preservative ranges	Moderate
Particle engineering	Defined particle-size distribution, morphology or surface treatment	Moderate to strong
Redispersion	Low-shear mixing or anti-caking system	Moderate
Palatability	Flavor-masking combination with specified sensory performance	Moderate
Packaging	Single-dose bottle, pouch, cup or sealed dispensing system	Moderate
Manufacturing	Order of addition, homogenization, deaeration or milling process	Moderate
Diagnostic use	Administration protocol linked to imaging quality or patient subgroup	Narrow
Device integration	Bottle, cap, straw, cup or dosing adapter	Moderate

The most defensible patent strategy would combine composition and process claims. A formulation patent limited to a broad list of conventional excipients may face obviousness and written-description challenges. Stronger claims would define measurable performance, such as:

• Maximum sedimentation after a specified storage period.
• Redispersion after a defined number of inversions.
• Viscosity at specified shear rates.
• Radiographic attenuation at a defined barium concentration.
• Particle-size distribution after storage.
• Microbial stability under multidose conditions.
• Reduced foaming during manufacture and administration.

Trade-secret protection may be more valuable than patent protection for mixing order, hydration time, shear profile, deaeration, filling temperature and hold-time controls. These process parameters can be difficult for competitors to reverse-engineer from the finished product.

What is the patent and Orange Book status of E-Z-PAQUE?

E-Z-PAQUE is an established barium sulfate diagnostic product, not a newly discovered chemical entity. The commercial product should not be analyzed like a branded small-molecule drug with a conventional patent-cliff timetable.

The relevant regulatory and IP points are:

• Barium sulfate products are regulated as drug products because they are used for diagnostic imaging.
• The active ingredient has no practical new-chemical-entity exclusivity.
• Public product labeling identifies formulation and safety information but does not establish a long remaining period of market exclusivity.
• Any current Orange Book patent listing, exclusivity entry or approved-product status must be assessed against the FDA’s live databases and the specific product identifier.[2]
• Formulation, packaging and manufacturing patents may exist outside the Orange Book or may not block an ANDA applicant if they are not listed or are not enforceable against the proposed product.

For a challenger, the critical diligence question is not simply whether E-Z-PAQUE has a patent. It is whether an enforceable claim reads on the proposed barium concentration, excipient ranges, manufacturing process, container and labeled use.

When does E-Z-PAQUE lose exclusivity and what generic entry risks exist?

E-Z-PAQUE’s core market protection is likely based on brand recognition, institutional purchasing, physician familiarity, manufacturing capability and regulatory history rather than a single patent expiration date.

Generic-entry risks arise through several pathways:

ANDA or abbreviated pathway

A competing barium sulfate product may pursue an abbreviated approval route where the FDA determines that the product can demonstrate pharmaceutical equivalence, bioequivalence or appropriate product-specific performance. For a nonabsorbed radiopaque suspension, conventional systemic bioequivalence may not be the central issue. The sponsor may instead need to address active ingredient identity, concentration, dosage form, route, quality attributes and clinical or imaging performance requirements.

505(b)(2) strategy

A 505(b)(2) application may be relevant when the sponsor relies partly on published information or an FDA finding for an approved product but introduces a meaningful formulation, dosage, packaging or use modification. Potential 505(b)(2) differentiation includes:

• Lower-viscosity formulations.
• Pediatric or dysphagia-focused presentations.
• New flavor systems.
• Extended shelf life.
• Unit-dose packaging.
• Reduced-volume high-density products.
• Products designed for specific imaging protocols.

Paragraph IV challenges

Paragraph IV certification becomes relevant only if an NDA patent is listed in the Orange Book and the applicant seeks approval before patent expiration. Because E-Z-PAQUE is an old diagnostic product, the commercial importance of a Paragraph IV strategy depends on whether active, listed patents cover the specific marketed formulation or delivery system.

A generic sponsor should not assume that absence of a publicly visible composition patent eliminates risk. Process patents, packaging patents, supplier agreements and non-Orange-Book litigation theories can still affect launch economics.

What excipient strategies offer the best commercial opportunities?

1. Low-viscosity, rapid-settling formulations

A product that pours easily but rapidly stabilizes after filling could improve patient experience and reduce preparation time. The technical challenge is balancing redispersion with sedimentation resistance.

Potential claims could cover a defined viscosity profile rather than a single viscosity value. This approach may provide broader protection across manufacturing lots and temperatures.

2. High-concentration, lower-volume dosing

A higher-density formulation could reduce the volume patients must swallow. The opportunity is strongest in dysphagia, pediatric and elderly populations. Development risks include increased viscosity, sedimentation, constipation, mouthfeel and radiographic artifacts.

3. Pediatric and sensory-optimized products

A fruit-flavored, lower-sugar, low-volume product could command a premium if it reduces repeat administration and incomplete imaging. Pediatric positioning would require careful excipient selection, age-appropriate labeling and stronger palatability evidence.

4. Preservative-free unit-dose systems

Unit-dose pouches, cups or bottles could reduce microbial-control requirements and simplify hospital workflow. The commercial advantage is greatest in high-throughput imaging centers and institutions with strict single-use procedures.

5. Sugar-free and electrolyte-controlled formulations

Patients with diabetes, renal disease or dietary restrictions may benefit from lower-sugar and lower-electrolyte options. These formulations require assessment of osmotic effects, taste masking and gastrointestinal tolerability.

6. Ready-to-use and powder-for-reconstitution formats

Ready-to-use products minimize pharmacy or radiology preparation. Powder formats can reduce shipping weight and improve shelf stability, but they shift risk to reconstitution accuracy, clumping, dust control and final-volume consistency.

7. Manufacturing-process differentiation

A proprietary particle-size reduction, surface-treatment or high-shear dispersion process could produce improved radiopacity at lower solids loading. Process patents and trade secrets may protect this opportunity more effectively than broad excipient claims.

How does E-Z-PAQUE compare with other barium sulfate products?

Commercial factor	E-Z-PAQUE-type product	Powder product	Low-density suspension	Premium differentiated product
Preparation	Ready to use	Requires reconstitution	Usually ready to use	Usually ready to use
Hospital labor	Low	Higher	Low	Low
Shipping efficiency	Lower	Higher	Lower	Variable
Patient volume	Standard	Depends on reconstitution	May be higher	Potentially lower
Excipient complexity	Higher	Moderate	Moderate	High
IP opportunity	Formulation and packaging	Reconstitution and process	Rheology and dose	Broadest
Price strategy	Value or parity	Cost advantage	Protocol-specific	Premium

E-Z-PAQUE competes in a fragmented market that includes branded barium sulfate products, generic suspensions, powders and specialized formulations. Purchasing decisions are influenced by supply reliability, radiologist preference, hospital contracts, reimbursement, product availability and ease of preparation.

Which companies and counterparties matter commercially?

Bracco Diagnostics is the central branded-product reference for E-Z-PAQUE. Competitive opportunities also involve:

• Generic pharmaceutical manufacturers with sterile or nonsterile suspension capabilities.
• Radiology contrast suppliers.
• Contract manufacturers with high-solids suspension expertise.
• Excipient suppliers providing hydrocolloids, flavors, sweeteners and wetting agents.
• Packaging companies offering unit-dose cups, pouches and tamper-evident systems.
• Hospital group-purchasing organizations.
• Imaging-center networks seeking standardized protocols.

Licensing opportunities are most credible around proprietary suspension technology, palatability systems, particle engineering and packaging. A licensing package should include formulation know-how, analytical methods, scale-up parameters and regulatory support. A bare excipient patent is less attractive than a validated product platform with comparative imaging and handling data.

What FDA regulatory issues affect an E-Z-PAQUE competitor?

A competing product must address active-ingredient quality, excipient safety, microbiological control, stability, container closure integrity, dose uniformity and radiographic performance. The FDA will also evaluate whether formulation changes alter the product’s clinical performance or safety profile.[1]

Key development studies include:

• Assay and identity of barium sulfate.
• Particle-size distribution.
• Sedimentation and redispersion.
• Viscosity across temperature ranges.
• Radiographic attenuation.
• Microbial limits and preservative effectiveness, where applicable.
• Extractables and leachables.
• Shipping and vibration stability.
• Flavor and patient acceptability.
• Compatibility with administration accessories.

For an established nonabsorbed diagnostic product, in vivo pharmacokinetic bioequivalence may have limited relevance. Comparative imaging performance and pharmaceutical quality can be more important, depending on the FDA pathway and product-specific requirements.

What revenue exposure and launch scenarios apply to E-Z-PAQUE?

The principal revenue exposure is institutional rather than retail. A challenger can target three launch scenarios:

1. Commodity substitution: Compete on price, supply reliability and contract access. This has the lowest differentiation and highest margin pressure.
2. Workflow substitution: Offer unit-dose, ready-to-use or low-preparation packaging. This supports hospital labor savings and switching incentives.
3. Clinical-segment differentiation: Target pediatric, dysphagia, low-volume or sugar-free use cases. This supports premium pricing but requires more evidence and focused sales execution.

The strongest commercial model is a platform with multiple SKUs using a common barium sulfate suspension base. Shared manufacturing and analytical methods can support adult, pediatric, low-volume and specialty-flavor products while reducing development cost.

Key Takeaways

• E-Z-PAQUE’s commercial value comes from formulation performance and workflow convenience, not chemical exclusivity.
• The key excipient functions are suspension control, wetting, rheology, taste masking, pH control and preservation.
• The most attractive opportunities are low-volume dosing, pediatric palatability, preservative-free unit-dose packaging and rapid-redispersion systems.
• Composition, process, packaging and performance-based claims offer stronger protection than broad claims listing conventional excipients.
• Generic and 505(b)(2) entry risk depends on the specific FDA pathway, listed patents, formulation similarity and manufacturing process.
• Trade-secret protection is important for mixing order, particle dispersion, deaeration, hold time and scale-up conditions.
• A differentiated product supported by imaging, handling and patient-acceptability data should have greater licensing value than an excipient-only patent.

FAQs about E-Z-PAQUE excipient strategy

Can a competitor use the same excipients as E-Z-PAQUE?

Yes, provided the proposed formulation meets FDA requirements and does not infringe enforceable claims covering the specific composition, process, packaging or use. Excipient identity alone generally does not establish infringement.

Is barium sulfate an excipient in E-Z-PAQUE?

No. Barium sulfate is the active radiopaque ingredient. The suspending agents, flavoring agents, sweeteners, buffers and preservatives are excipients.

What is the best formulation opportunity for a generic E-Z-PAQUE product?

A ready-to-use, low-viscosity product with rapid redispersion, acceptable flavor and unit-dose packaging offers the clearest opportunity to compete beyond price.

Can a new flavor support patent protection?

A flavor alone is usually weak patent subject matter. Protection is stronger when the flavor is part of a defined taste-masking system that produces measurable improvements in palatability, stability or administration performance.

Are biosimilars relevant to E-Z-PAQUE?

No. E-Z-PAQUE contains an inorganic small-molecule diagnostic active, barium sulfate. It is not a biologic and does not create a biosimilar pathway.

References

1. U.S. Food and Drug Administration. (n.d.). E-Z-PAQUE: Barium sulfate oral suspension prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
3. Bracco Diagnostics Inc. (n.d.). E-Z-PAQUE product information. Bracco Diagnostics.
4. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. FDA.